Initiator Pharma’s annual report for 2020 is now available on the company’s home page
For more information about Initiator Pharma, please contact:
Claus Elsborg Olesen, CEO
Telephone number: +45 6126 0035
About Initiator Pharma
Initiator Pharma is a clinical-stage biotechnology company based in Aarhus, Denmark. The company’s main clinical Phase assets are IPED2015, intended for patients with erectile dysfunction, and IP2018, for the treatment of psychogenic erectile dysfunction. The treatments both represent First in Class treatments for psychogenic and organic ED, respectively, and are expected to improve the quality of life for a growing number of patients who are not responding to or cannot be treated with existing drugs on the market. Recently, Initiator Pharma have also announced its plans to expand the clinical development pipeline to include a new program for Neuropathic Pain, more specifically the Orphan indication Trigeminal Neuralgia. Read more on www.initiatorpharma.com.